Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Abstract | BACKGROUND: METHODS: This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT04276688. FINDINGS: Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3-7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5-11]) than the control group (12 days [8-15]; hazard ratio 4·37 [95% CI 1·86-10·24], p=0·0010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir- ritonavir because of biochemical hepatitis. No patients died during the study. INTERPRETATION: FUNDING: The Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine.
|
Authors | Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso, Raymond Liu, Tom Wai-Hin Chung, Man-Yee Chu, Yuk-Yung Ng, Jenny Lo, Jacky Chan, Anthony Raymond Tam, Hoi-Ping Shum, Veronica Chan, Alan Ka-Lun Wu, Kit-Man Sin, Wai-Shing Leung, Wai-Lam Law, David Christopher Lung, Simon Sin, Pauline Yeung, Cyril Chik-Yan Yip, Ricky Ruiqi Zhang, Agnes Yim-Fong Fung, Erica Yuen-Wing Yan, Kit-Hang Leung, Jonathan Daniel Ip, Allen Wing-Ho Chu, Wan-Mui Chan, Anthony Chin-Ki Ng, Rodney Lee, Kitty Fung, Alwin Yeung, Tak-Chiu Wu, Johnny Wai-Man Chan, Wing-Wah Yan, Wai-Ming Chan, Jasper Fuk-Woo Chan, Albert Kwok-Wai Lie, Owen Tak-Yin Tsang, Vincent Chi-Chung Cheng, Tak-Lun Que, Chak-Sing Lau, Kwok-Hung Chan, Kelvin Kai-Wang To, Kwok-Yung Yuen |
Journal | Lancet (London, England)
(Lancet)
Vol. 395
Issue 10238
Pg. 1695-1704
(05 30 2020)
ISSN: 1474-547X [Electronic] England |
PMID | 32401715
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2020 Elsevier Ltd. All rights reserved. |
Chemical References |
- Drug Combinations
- lopinavir-ritonavir drug combination
- Interferon beta-1b
- Lopinavir
- Ribavirin
- Ritonavir
|
Topics |
- Adult
- Betacoronavirus
- COVID-19
- Coronavirus Infections
(drug therapy)
- Drug Combinations
- Drug Therapy, Combination
- Female
- Hong Kong
- Hospitalization
- Humans
- Interferon beta-1b
(therapeutic use)
- Lopinavir
(therapeutic use)
- Male
- Middle Aged
- Pandemics
- Pneumonia, Viral
(drug therapy)
- Ribavirin
(therapeutic use)
- Ritonavir
(therapeutic use)
- SARS-CoV-2
- COVID-19 Drug Treatment
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|